391 completed, 57 terminated, 35 unknown, 34 recruiting. 559 Phase 2, 65 Phase 1, 41 Phase 3.
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| cfMSC Stem Cell Therapy Targeting COPD clonal fetal MSCs - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-27 |
| The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD Inhaled Nitric Oxide, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 80 | 2026-12-01 | 2026-07-08 |
| A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease TQC3927 inhalation aerosol, Glyceryl bromide/formoterol inhalation aerosol - Chronic Obstructive Pulmonary Disease | Phase 2 | Suspended | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 90 | 2026-12-01 | 2026-09-03 |
| Urolithin A Supplementation During Pulmonary Rehabilitation in Patients With COPD Urolithin A, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Not yet recruiting | Bryan A. Ross | 198 | 2026-11-01 | 2026-10-13 |
| A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease RO7830698, Placebo - Chronic Obstructive Pulmonary Disease (COPD), Healthy Participants | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 104 | 2026-10-20 | 2026-10-20 |
| A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease Stem cells - Chronic Obstructive Lung Disease | Phase 1 / Phase 2 | Not yet recruiting | SMSbiotech | 125 | 2026-10-01 | 2026-10-13 |
| Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients AERO-001, AERO-002, AERO-007 - COPD, Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Recruiting | AeroRx Therapeutics Inc. | 64 | 2026-10-01 | 2026-10-28 |
| GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD Tirzepatide - COPD, Obesity & Overweight | Phase 2 | Not yet recruiting | The Cleveland Clinic | 30 | 2026-08-28 | 2026-08-05 |
| PRA-216 COPD Safety and Biomarker Study PRA-216, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Recruiting | Prana Therapies Inc | 40 | 2026-08-25 | 2026-10-28 |
| Rademikibart IV for Acute Asthma and COPD Exacerbation Rademikibart - Asthma Acute, COPD Exacerbation Acute | Phase 2 | Recruiting | Connect Biopharm LLC | 40 | 2026-08-21 | 2026-10-27 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) Brenipatide, Placebo, Standard of Care - Pulmonary Disease, Chronic Obstructive | Phase 2 | Recruiting | Eli Lilly and Company | 606 | 2026-08-07 | 2026-10-08 |
| A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD KIT2014, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 / Phase 2 | Recruiting | Kither Biotech Srl | 36 | 2026-08-05 | 2026-10-20 |
| A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis Galvokimig, Placebo - Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | Phase 2 | Recruiting | UCB Biopharma SRL | 402 | 2026-07-27 | 2026-10-27 |
| A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease HRS-9821 Inhalation Suspension, HRS-9821 Placebo Inhalation Suspension - COPD | Phase 2 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 90 | 2026-07-20 | 2026-08-18 |
| To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Recruiting | Expedition Therapeutics, Inc | 600 | 2026-06-30 | 2026-10-28 |
| A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) WIN378, Placebo - COPD (Chronic Obstructive Pulmonary Disease) | Phase 2 | Recruiting | Windward Bio | 105 | 2026-06-02 | 2026-10-23 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection XKH001Injection, Placebo - COPD | Phase 2 | Not yet recruiting | Zhejiang Kanova Biopharmaceutical Co., LTD | 75 | 2026-04-01 | 2026-04-09 |
| A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease RSS0343 tablets, RSS0343 tablets Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | Reistone Biopharma Company Limited | 300 | 2026-03-10 | 2026-06-05 |
| Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD HSK39004 Dry Powder Inhaler -0.75mg BID - Chronic Obstructive Lung Disease (COLD) | Phase 2 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 300 | 2026-03-01 | 2026-02-25 |
| Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 % - Chronic Obstructive Pulmonary Disease (COPD), Allergies | Phase 2 | Recruiting | Johns Hopkins University | 334 | 2026-02-12 | 2026-09-04 |
Showing 20 of 559. Sign in to see all of them.
Emphysema (56) · Bronchitis, Chronic (36) · Asthma (29) · Lung Diseases (26) · Dyspnea (18) · Pulmonary Emphysema (17) · Respiratory Aspiration (15) · Inflammation (12) · Respiration Disorders (12) · Hypertension, Pulmonary (11) · Lung Diseases, Obstructive (11) · Motor Activity (9) · Bronchiolitis Obliterans Syndrome (8) · Heart Failure (7)
Chronic Disease (559) · Disease Attributes (559) · Pathological Conditions, Signs and Symptoms (559) · Pathologic Processes (555) · Respiratory Tract Diseases (553) · Lung Diseases, Obstructive (548) · Lung Diseases (533) · Bronchial Diseases (76) · Infections (45) · Immune System Diseases (43) · Respiration Disorders (43) · Respiratory Tract Infections (42) · Bronchitis (40) · Signs and Symptoms (35) · Hypersensitivity (32)
Tiotropium Bromide (36) · Formoterol Fumarate (31) · Salmeterol Xinafoate (14) · Glycopyrrolate (13) · indacaterol (11) · Fluticasone (8) · Roflumilast (8) · aclidinium bromide (8) · Albuterol (7) · Inhalation (7) · Exercise (6) · GSK573719 (6) · Ipratropium (6) · 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide (5) · Aspirin (5)
GlaxoSmithKline (46) · AstraZeneca (42) · Boehringer Ingelheim (33) · Chiesi Farmaceutici S.p.A. (19) · Novartis (13) · Novartis Pharmaceuticals (13) · Pearl Therapeutics, Inc. (13) · Pfizer (12) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (10) · Aeris Therapeutics (8) · Merck Sharp & Dohme LLC (7) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (6) · Dey (6) · US Department of Veterans Affairs (6) · Haisco Pharmaceutical Group Co., Ltd. (5)
United States (224) · United Kingdom (107) · Germany (103) · Canada (57) · Poland (49) · Netherlands (47) · China (38) · Australia (35) · Spain (33) · Hungary (32) · Argentina (30) · Bulgaria (29) · Belgium (28) · Denmark (26) · Russia (26)
Dave Singh, MD (9) · Esther Garcia, MD (7) · Colin Reisner, M.D. (6) · Dave Singh (4) · Adam Wanner, MD (3) · Gerard Criner, MD (3)
PMID 24432712, PMID 25287629, PMID 33124005, PMID 19179484, PMID 20920189, PMID 21184620, PMID 22374920, PMID 22465313, PMID 22793945, PMID 29202767, PMID 29975735, PMID 30116551, PMID 34887657, PMID 37192443, PMID 12543832, PMID 15319045, PMID 16235359, PMID 16565429, PMID 16611654, PMID 16636091, PMID 16690673, PMID 16796497, PMID 17132052, PMID 17296644, PMID 17507545, PMID 17715164, PMID 18073405, PMID 18202351, PMID 18245142, PMID 18655841, PMID 18684848, PMID 18723437, PMID 18972276, PMID 19017883, PMID 19135348, PMID 19213793, PMID 19436683, PMID 19460848, PMID 19583857, PMID 19750190, PMID 20007923, PMID 20008582, PMID 20025989, PMID 20090057, PMID 20154234, PMID 20299628, PMID 20416390, PMID 20442544, PMID 20463178, PMID 20541381
2015 (10), 2018 (9), 2017 (7), 2009 (6), 2014 (5), 2008 (2), 2016 (2), 2019 (2), R01HL131960 (2), R33AT009991 (2), 2005 (1), 2023 (1), 2025 (1), 4UH3TR002450-02 (1), I01CX002543 (1)